Liu R, Yang B, Deng Z, et al. - Through electronically searching Medline, EMBASE, and CENTRAL database from 1997 to December 2019, researchers sought to compare the safety and effectiveness of verapamil and triamcinolone acetonide (TAC) for the treatment of keloids and hypertrophic scars. Five randomized controlled trials were involved, consisting of a total of 215 patients (273 scars). No major differences in the reduction in height, vascularity, pliability, and degree of pigmentation were found between verapamil and TAC. The findings demonstrated that, when verapamil was used, the frequency of telangiectasia and skin atrophy were substantially lower than for TAC. TAC performed better than verapamil in the treatment of keloids and hypertrophic scars while verapamil was safer than TAC. In addition, there was no clear evidence that verapamil was more or less effective than TAC. Considering the high degree of protection of verapamil, the authors recommend that if TAC results in adverse effects, verapamil should be used as an alternative treatment.